Table 6.
Variables | Treatment | Placebo BID | PG 500 mg BID | PG 1000 mg BID | Reference range |
---|---|---|---|---|---|
Total protein (g/dL) | Before | 7.6±0.4 | 7.5±0.3 | 7.5±0.3 | 6.4–8 3 |
After | 7.6±0.4 | 7.6±0.4 | 7.6±0.3 | ||
Albumin (g/dL) | Before | 4.6±0.2 | 4.5±0.2 | 4.6±0.2 | 3.8–5.1 |
After | 4.5±0.2 | 4.5±0.2 | 4.5±0.2 | ||
A/G ratio | Before | 1.5±0.2 | 1.5±0.2 | 1.6±0.2 | |
After | 1.5±0.2 | 1.5±0.2 | 1.5±0.1 | ||
T. bilirubin (mg/dL) | Before | 0.8±0.3 | 0.8±0.3 | 0.7±0.2 | 0.1–1.2 |
After | 0.8±0.3 | 0.8±0.2 | 0.8±0.3 | ||
AST (IU/L) | Before | 19.8±3.2 | 21.7±6.1 | 20.8±5.4 | 0–40 |
After | 20.9±8.0 | 21.6±6.4 | 20.7±4.7 | ||
ALT (IU/L) | Before | 14.8±6.8 | 17.5±8.0 | 16.3±8.3 | 0–40 |
After | 16.3±10.2 | 17.7±9.0 | 16.2±5.8 | ||
ALP (IU/L) | Before | 57.5±12.7 | 59.1±14.3 | 59.8±19.9 | 30–120 |
After | 57.4±14.2 | 59.1±15.8 | 59.4±19.7 | ||
r‐GTP (IU/L) | Before | 15.1±6.7 | 16.7±7.8 | 15.5±6.1 | 0–64 |
After | 14.3±5.0 | 17.5±14.9 | 15.1±5.8 | ||
Cholesterol (mg/dL) | Before | 189.2±31.0 | 195.9±31.3 | 197.9±41.8 | 140–271 |
After | 188.0±25.5 | 194.1±29.5 | 200.8±47.0 | ||
Triglycerides (mg/dL) | Before | 103.0±68.1 | 108.0±65.2 | 96.6±64.3 | 130–220 |
After | 112.0±70.3 | 117.3±77.4 | 107.6±64.3 | ||
HDL‐Chol (mg/dL) | Before | 55.5±11.4 | 53.8±11.4 | 55.4±10.6 | 42–88 |
After | 54.0±11.1 | 53.6±11.0 | 54.9±10.2 | ||
Glucose (mg%) | Before | 86.9±7.6 | 86.5±7.4 | 87.2±9.2 | 70–115 |
After | 89.3±8.1 | 88.8±7.3 | 89.4±9.3 | ||
Creatinine (mg/dL) | Before | 0.7±0.1 | 0.7±0.1 | 0.7±0.1 | 0.4–1.5 |
After | 0.8±0.1 | 0.8±0.1 | 0.8±0.1 | ||
BUN (mg/dL) | Before | 12.5±3.3 | 12.5±2.7 | 12.6±3.0 | 5–24 |
After | 12.4±3.2 | 11.4±2.4 | 12.8±3.4 |
Data are expressed as mean±standard deviation.
A/G, albumin to globulin ratio; T. bilirubin, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; r-GTP, gamma-glutamyl transpeptidase; HDL-Chol, high-density lipoprotein cholesterol; BUN, blood urea nitrogen.